C5b-9 terminal complex protects oligodendrocytes from apoptotic cell death by inhibiting caspase-8 processing and up-regulating FLIP

Journal of Immunology

Volumn 176, Issue 5, 2006, Pages 3173-3180

  Cudrici, Cornelia ^a   Niculescu, Florin ^a   Jensen, Timothy ^a   Zafranskaia, Ekaterina ^a   Fosbrink, Matthew ^a   Rus, Violeta ^a   Shin, Moon L ^a   Rus, Horea ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BENZYLOXYCARBONYLISOLEUCYLGLUTAMYLTHREONYLASPARTYL FLUOROMETHYL KETONE; BETA ACTIN; CASPASE 8; CASPASE 8 INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; FAS ANTIGEN; FAS LIGAND; FLICE INHIBITORY PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BID;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL DIFFERENTIATION; CELL SURVIVAL; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME INHIBITION; FLOW CYTOMETRY; IMMUNOPRECIPITATION; MITOCHONDRION; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; RAT; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 33644516274     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.176.5.3173     Document Type: Article

References (50)

1. Trapp, B. D., A. Nishiyama, D. Cheng, and W. Macklin. 1997. Differentiation and death of premyelinating oligodendrocytes in developing rodent brain. J. Cell Biol. 137: 459-468.
2. Tang, D. G., Y. M. Tokumoto, J. A. Apperly, A. C. Lloyd, and M. C. Raff. 2001. Lack of replicative senescence in cultured rat oligodendrocyte precursor cells. Science 291: 868-871.
3. Billon, N., C. Jolicoeur, Y. Tokumoto, B. Vennstrom, and M. Raff. 2002. Normal timing of oligodendrocyte development depends on thyroid hormone receptor α 1 (TRα1). EMBO J. 21: 6452-6460.
4. Barres, B. A., and M. C. Raff. 1999. Axonal control of oligodendrocyte development. J. Cell Biol. 147: 1123-1128.
5. Raine, C. S. 1997. The Norton Lecture: a review of the oligodendrocyte in the multiple sclerosis lesion. J. Neuroimmunol. 77: 135-152.
6. Sabelko-Downes, K. A., J. H. Russell, and A. H. Cross. 1999. Role of Fas-FasL interactions in the pathogenesis and regulation of autoimmune demyelinating disease. J. Neuroimmunol. 100: 42-52.
7. 2-terminal kinase-3. Brain 126: 1358-1370.
8. Barnett, M. H., and J. W. Prineas. 2004. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55: 458-468.
9. Lucchinetti, C., W. Bruck, J. Parisi, B. Scheithauer, M. Rodriguez, and H. Lassmann. 2000. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47: 707-717.
10. Dowling, P., W. Husar, J. Menonna, H. Donnenfeld, S. Cook, and M. Sidhu. 1997. Cell death and birth in multiple sclerosis brain. J. Neurol. Sci. 149: 1-11.
11. Bonetti, B., and C. S. Raine. 1997. Multiple sclerosis: oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis. Ann. Neurol. 42: 74-84.
12. D'Souza, S. D., B. Bonetti, V. Balasingam, N. R. Cashman, P. A. Barker, A. B. Troutt, C. S. Raine, and J. P. Antel. 1996. Multiple sclerosis: Fas signaling in oligodendrocyte cell death. J. Exp. Med. 184: 2361-2370.
13. Choi, C., and E. N. Benveniste. 2004. Fas ligand/Fas system in the brain: regulator of immune and apoptotic responses. Brain Res. Brain Res. Rev. 44: 65-81.
14. Chinnaiyan, A. M., K. O'Rourke, M. Tewari, and V. M. Dixit. 1995. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81: 505-512.
15. Boldin, M. P., T. M. Goncharov, Y. V. Goltsev, and D. Wallach. 1996. Involvement of MACH, a novel MORT1/FADD-imeracting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell 85: 803-815.
16. Kischkel, F. C., S. Hellbardt, I. Behrmann, M. Germer, M. Pawlita, P. H. Krammer, and M. E. Peter. 1995. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14: 5579-5588.
17. Li, H., H. Zhu, C. J. Xu, and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501.
18. Esposti, M. D. 2002. The roles of Bid. Apoptosis 7: 433-440.
19. Luo, X., I. Budihardjo, H, Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490.
20. Desagher, S., A. Osen-Sand, A. Nichols, R. Eskes, S. Montessuit, S. Lauper, K. Maundrell, B. Antonsson, and J.-C. Martinou. 1999. Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome C release during apoptosis. J. Cell Biol. 144: 891-901.
21. Thome, M., and J. Tschopp. 2001. Regulation of lymphocyte proliferation and death by FLIP. Nat. Rev. Immunol. 1: 50-58.
22. Micheau, O., S. Lens, O. Gaide, K. Alevizopoulos, and J. Tschopp. 2001. NF-κB signals induce the expression of c-FLIP. Mol. Cell. Biol. 21: 5299-5305.
23. Krueger, A., I. Schmitz, S. Baumann, P. H. Krammer, and S. Kirchhoff. 2001. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J. Biol. Chem. 276: 20633-20640.
24. Hu, W.-H., H. Johnson, and H.-B. Shu. 2000. Activation of NF-κB by FADD, casper, and caspase-8. J. Biol. Chem. 275: 10838-10844.
25. Rus, H., and F. Niculescu. 2001. The complement system in central nervous system diseases. Immunol. Res. 24: 79-86.
26. Papadimitriou, J. C., L. E. Ramm, C. B. Drachenberg, B. F. Trump, and M. L. Shin. 1991. Quantitative analysis of adenine nucleotides during the prelytic phase of cell death mediated by C5b-9. J. Immunol. 147: 212-217.
27. Papadimitriou, J. C., C. B. Drachenberg, M. L. Shin, and B. F. Trump. 1994. Ultrastructural studies of complement mediated cell death: a biological reaction model to plasma membrane injury. Virchows Arch. 424: 677-685.
28. Cragg, M. S., W. J. Howatt, L. Bloodworth, V. A. Anderson, B. P. Morgan, and M. J. Glennie. 2000. Complement mediated cell death is associated with DNA fragmentation. Cell Death. Differ. 7: 48-58.
29. Carney, D. F., C. L. Koski, and M. L. Shin. 1985. Elimination of terminal complement intermediates from the plasma membrane of nucleated cells: the rate of disappearance differs for cells carrying C5b-7 or C5b-8 or a mixture of C5b-8 with a limited number of C5b-9. J. Immunol. 134: 1804-1809.
30. Scolding, N. J., B. P. Morgan, W. A. Houston, C. Linington, A. K. Campbell, and D. A. Compston. 1989. Vesicular removal by oligodendrocytes of membrane attack complexes formed by activated complement. Nature 339: 620-622.
31. Soane, L., H. Rus, F. Niculescu, and M. L. Shin. 1999. Inhibition of oligodendrocyte apoptosis by sublytic C5b-9 is associated with enhanced synthesis of bcl-2 and mediated by inhibition of caspase-3 activation. J. Immunol. 163: 6132-6138.
32. Soane, L., H. J. Cho, F. Niculescu, H. Rus, and M. L. Shin. 2001. C5b-9 terminal complement complex protects oligodendrocytes from death by regulating Bad through phosphatidylinositol 3-kinase/Akt pathway. J. Immunol. 167: 2305-2311.
33. Rus, H. G., F. Niculescu, and M. L. Shin. 1996. Sublytic complement attack induces cell cycle in oligodendrocytes. J. Immunol. 156: 4892-4900.
34. Rus, H., F. Niculescu, T. Badea, and M. L. Shin. 1997. Terminal complement complexes induce cell cycle entry in oligodendrocytes through mitogen activated protein kinase pathway. Immunopharmacology 38: 177-187.
35. Niculescu, F., H. Rus, T. van Biesen, and M. L. Shin. 1997. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 158: 4405-4412.
36. Nauta, A. J., M. R. Daha, O. Tijsma, B. van de Water, F. Tedesco, and A. Roos. 2002. The membrane attack complex of complement induces caspase activation and apoptosis. Eur. J. Immunol. 32: 783-792.
37. Zwaka, T. P., J. Torzewski, A. Hoeflich, M. Dejosez, S. Kaiser, V. Hombach, and P. M. Jehle. 2003. The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop. FASEB J. 17: 1346-1348.
38. Scaffidi, C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, K. J. Tomaselli, K. M. Debatin, P. H. Krammer, and M. E. Peter. 1998. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17: 1675-1687.
39. Van Parijs, L., Y. Refaeli, A. K. Abbas, and D. Baltimore. 1999. Autoimmunity as a consequence of retrovirus-mediated expression of C-FLIP in lymphocytes. Immunity 11:763-770.
40. Lens, S. M., T. Kataoka, K. A. Fortner, A. Tinel, I. Ferrero, R. H. MacDonald, M. Hahne, F. Beermann, A. Attinger, H. A. Orbea, et al. 2002. The caspase 8 inhibitor c-FLIP(L) modulates T-cell receptor-induced proliferation but not activation-induced cell death of lymphocytes. Mol. Cell. Biol. 22: 5419-5433.
41. Budd, R. C. 2002. Death receptors couple to both cell proliferation and apoptosis. J. Clin. Invest. 109: 437-441.
42. Varadhachary, A. S., M. E. Peter, S. N. Perdow, P. H. Krammer, and P. Salgame. 1999. Selective up-regulation of phosphatidylinositol 3′-kinase activity in Th2 cells inhibits caspase-8 cleavage at the death-inducing complex: a mechanism for Th2 resistance from Fas-mediated apoptosis. J. Immunol. 163: 4772-4779.
43. Varadhachary, A. S., M. Edidin, A. M. Hanlon, M. E. Peter, P. H. Krammer, and P. Salgame. 2001. Phosphatidylinositol 3′-kinase blocks CD95 aggregation and caspase-8 cleavage at the death-inducing signaling complex by modulating lateral diffusion of CD95. J. Immunol. 166: 6564-6569.
44. Jones, R. G., A. R. Elford, M. J. Parsons, L. Wu, C. M. Krawczyk, W. C. Yeh, R. Hakem, R. Rottapel, J. R. Woodgett, and P. S. Ohashi. 2002. CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J. Exp. Med. 196: 335-348.
45. Gomez-Angelats, M., and J. A. Cidlowski. 2001. Protein kinase C regulates FADD recruitment and death-inducing signaling complex formation in Fas/CD95-induced apoptosis. J. Biol Chem. 276: 44944-44952.
46. Holmstrom, T. H., I. Schmitz, T. S. Soderstrom, M. Poukkula, V. L. Johnson, S. C. Chow, P. H. Krammer, and J. E. Eriksson. 2000. MAPK/ERK signaling in activated T cells inhibits CD95/Fas-mediated apoptosis downstream of DISC assembly. EMBO J. 19: 5418-5428.
47. Kennedy, N. J., T. Kataoka, J. Tschopp, and R. C. Budd. 1999. Caspase activation is required for T cell proliferation. J. Exp. Med. 190: 1891-1896.
48. Kang, T.-B., T. Ben-Moshe, E. E. Varfolomeev, Y. Pewzner-Jung, N. Yogev, A. Jurewicz, A. Waisman, O. Brenner, R. Haffner, E. Gustafsson, et al. 2004. Caspase-8 serves both apoptotic and nonapoptotic roles. J. Immunol. 173: 2976-2984.
49. Mogi, M., and A. Togari. 2003. Activation of caspases is required for osteoblastic differentiation. J. Biol. Chem. 278: 47477-47482.
50. Linington, C., H. Lassmann, B. P. Morgan, and D. A. Compston. 1989. Immunohistochemical localisation of terminal complement component C9 in experimental allergic encephalomyelitis. Acta Neuropathol. 79: 78-85.